AMZN vs. NVO: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AMZN and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
AMZN is a standard domestic listing, while NVO trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | AMZN | NVO |
|---|---|---|
| Company Name | Amazon.com, Inc. | Novo Nordisk A/S |
| Country | United States | Denmark |
| GICS Sector | Consumer Discretionary | Health Care |
| GICS Industry | Broadline Retail | Pharmaceuticals |
| Market Capitalization | 2,430.96 billion USD | 244.20 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | May 15, 1997 | April 30, 1981 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of AMZN and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AMZN | NVO |
|---|---|---|
| 5-Day Price Return | -0.03% | 4.72% |
| 13-Week Price Return | 12.23% | -17.05% |
| 26-Week Price Return | 0.58% | -37.87% |
| 52-Week Price Return | 29.42% | -60.23% |
| Month-to-Date Return | -2.64% | 15.71% |
| Year-to-Date Return | 3.90% | -41.70% |
| 10-Day Avg. Volume | 35.82M | 6.68M |
| 3-Month Avg. Volume | 43.43M | 6.63M |
| 3-Month Volatility | 27.21% | 65.20% |
| Beta | 1.30 | 1.52 |
Profitability
Return on Equity (TTM)
AMZN
23.84%
Broadline Retail Industry
- Max
- 49.17%
- Q3
- 28.98%
- Median
- 19.22%
- Q1
- 10.86%
- Min
- -11.14%
AMZN’s Return on Equity of 23.84% is on par with the norm for the Broadline Retail industry, indicating its profitability relative to shareholder equity is typical for the sector.
NVO
77.86%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
AMZN
10.54%
Broadline Retail Industry
- Max
- 19.78%
- Q3
- 11.90%
- Median
- 8.63%
- Q1
- 5.21%
- Min
- 0.82%
AMZN’s Net Profit Margin of 10.54% is aligned with the median group of its peers in the Broadline Retail industry. This indicates its ability to convert revenue into profit is typical for the sector.
NVO
35.61%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
NVO’s Net Profit Margin of 35.61% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
AMZN
11.37%
Broadline Retail Industry
- Max
- 27.23%
- Q3
- 15.96%
- Median
- 11.13%
- Q1
- 8.31%
- Min
- 1.77%
AMZN’s Operating Profit Margin of 11.37% is around the midpoint for the Broadline Retail industry, indicating that its efficiency in managing core business operations is typical for the sector.
NVO
45.78%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
NVO’s Operating Profit Margin of 45.78% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | AMZN | NVO |
|---|---|---|
| Return on Equity (TTM) | 23.84% | 77.86% |
| Return on Assets (TTM) | 11.14% | 24.22% |
| Net Profit Margin (TTM) | 10.54% | 35.61% |
| Operating Profit Margin (TTM) | 11.37% | 45.78% |
| Gross Profit Margin (TTM) | 49.61% | 83.95% |
Financial Strength
Current Ratio (MRQ)
AMZN
1.02
Broadline Retail Industry
- Max
- 3.54
- Q3
- 2.42
- Median
- 1.49
- Q1
- 1.22
- Min
- 0.67
AMZN’s Current Ratio of 1.02 falls into the lower quartile for the Broadline Retail industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
NVO
0.78
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
AMZN
0.15
Broadline Retail Industry
- Max
- 2.14
- Q3
- 1.34
- Median
- 0.63
- Q1
- 0.27
- Min
- 0.00
Falling into the lower quartile for the Broadline Retail industry, AMZN’s Debt-to-Equity Ratio of 0.15 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
NVO
0.59
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
AMZN
0.62
Broadline Retail Industry
- Max
- 37.34
- Q3
- 20.63
- Median
- 11.28
- Q1
- 4.22
- Min
- -19.29
AMZN’s Interest Coverage Ratio of 0.62 is a critical concern. A value below 1.0 means operating earnings are insufficient to cover interest expenses, indicating severe financial strain and high default risk.
NVO
149.07
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | AMZN | NVO |
|---|---|---|
| Current Ratio (MRQ) | 1.02 | 0.78 |
| Quick Ratio (MRQ) | 0.81 | 0.56 |
| Debt-to-Equity Ratio (MRQ) | 0.15 | 0.59 |
| Interest Coverage Ratio (TTM) | 0.62 | 149.07 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AMZN
0.00%
Broadline Retail Industry
- Max
- 5.46%
- Q3
- 2.38%
- Median
- 0.43%
- Q1
- 0.00%
- Min
- 0.00%
AMZN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
NVO
3.30%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
NVO’s Dividend Yield of 3.30% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
AMZN
0.00%
Broadline Retail Industry
- Max
- 131.17%
- Q3
- 63.48%
- Median
- 29.43%
- Q1
- 0.00%
- Min
- 0.00%
AMZN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
NVO
61.60%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | AMZN | NVO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 3.30% |
| Dividend Payout Ratio (TTM) | 0.00% | 61.60% |
Valuation
Price-to-Earnings Ratio (TTM)
AMZN
34.03
Broadline Retail Industry
- Max
- 66.12
- Q3
- 35.17
- Median
- 16.29
- Q1
- 10.47
- Min
- 5.94
AMZN’s P/E Ratio of 34.03 is within the middle range for the Broadline Retail industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
NVO
13.91
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.91 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
AMZN
3.59
Broadline Retail Industry
- Max
- 5.40
- Q3
- 3.33
- Median
- 2.04
- Q1
- 0.80
- Min
- 0.16
AMZN’s P/S Ratio of 3.59 is in the upper echelon for the Broadline Retail industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
NVO
4.95
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
NVO’s P/S Ratio of 4.95 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
AMZN
6.98
Broadline Retail Industry
- Max
- 9.06
- Q3
- 5.22
- Median
- 3.48
- Q1
- 1.90
- Min
- 0.74
AMZN’s P/B Ratio of 6.98 is in the upper tier for the Broadline Retail industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
NVO
8.87
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | AMZN | NVO |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 34.03 | 13.91 |
| Price-to-Sales Ratio (TTM) | 3.59 | 4.95 |
| Price-to-Book Ratio (MRQ) | 6.98 | 8.87 |
| Price-to-Free Cash Flow Ratio (TTM) | 111.85 | 23.46 |